HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY by Jiahua Qian et al.
2000 95: 1324-1329
 
 
Jiahua Qian, Mary Collins, Arlene H. Sharpe and Leon W. Hoyer
 
Prevention and treatment of factor VIII inhibitors in murine hemophilia A
 
http://www.bloodjournal.org/content/95/4/1324.full.html
Updated information and services can be found at:
 (2494 articles) Hemostasis, Thrombosis, and Vascular Biology     
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of
For personal use only. on November 2, 2014.  by guest    www.bloodjournal.org From  For personal use only. on November 2, 2014.  by guest    www.bloodjournal.org From HEMOSTASIS, THROMBOSIS,AND VASCULAR BIOLOGY
Prevention and treatment of factor VIII inhibitors in murine hemophiliaA
Jiahua Qian, Mary Collins,Arlene H. Sharpe, and Leon W. Hoyer
Inhibitory antibody formation is a major
complication of factor VIII replacement
therapy in patients with hemophilia A. To
better understand the pathogenesis of
this immunologic reaction, we evaluated
the role of T-cell costimulatory signals for
antifactor VIII antibody formation in a
murine model of hemophilia A. Repeated
intravenous injections of factor VIII in
these factor VIII–deﬁcient mice induced
an antifactor VIII inhibitor antibody re-
sponse. This response was shown to be
T-cell dependent by its absence in hemo-
philic mice also deﬁcient for the T-cell
costimulatory ligand B7-2. In separate
experiments,injectionofmurineCTLA4-Ig
completely blocked the primary response
to factor VIII in hemophilic mice with
intact B7 function. This reagent also
prevented or diminished further in-
creases in antifactor VIII when given to
hemophilic mice with low antifactor VIII
antibody titers. These studies suggest
that strategies targeting the B7-CD28
pathway are potential therapies to pre-
vent and treat inhibitory antifactor VIII
antibodies. Moreover, because the devel-
opment of antibodies to replaced pro-
teins may limit the success of many
human gene therapy approaches, our
resultsmaybebroadlyapplicable.(Blood.
2000;95:1324-1329)
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Introduction
Hemophilia A is an X-linked bleeding disorder caused by the
deﬁciency in plasma of the glycoprotein factor VIII.1 However,
approximately one-third of patients with severe hemophilia A
develop an antifactor VIII inhibitor following factor VIII replace-
ment therapy.2 Current strategies to blunt the antibody response in
these patients have only been marginally successful. Moreover, the
development of antibodies to replaced proteins is a critical problem
that needs to be solved if gene therapy is to be successful in the
treatment of hemophilias and other deﬁciency diseases.3,4
We have used a mouse model of hemophilia A to evaluate new
methods for the prevention and treatment of inhibitor formation.
Hemophilia A mice, generated by targeted disruption of exon 16
(E-16) of the factor VIII gene, have no detectable factor VIII
activity in their plasma5 and are similar in this way to patients with
severe hemophiliaA.As expected, hemophiliaAmice have in vivo
signs of a coagulation pathway defect with fatal bleeding if tails are
cut without use of hemostatic measures, and they develop subcuta-
neous and intramuscular bleeding after handling or temporary
immobilization.6-8
Intravenous infusions of 0.2 µg human factor VIII, a dose
equivalent on a weight basis to that given to hemophiliaApatients,
resulted in minimal or no antibody response in these hemophilia A
mice after a single injection, but repeat infusions led to high titer
inhibitory antifactor VIII.6 However, before antibodies were de-
tected, a factor VIII–speciﬁc T-cell proliferative response was
detected 3 days after the ﬁrst exposure to human factor VIII. This
suggested that the antibody response to factor VIII is T-cell
dependent, so that blockade of T-cell activation might prevent
inhibitor antibody formation in hemophiliaAmice.
OptimalT-cellactivationrequiressignalingthroughtheantigen-
speciﬁc T-cell receptor (TCR) by its engagement with peptide
major histocompatibility complex (MHC) complexes on antigen-
presenting cells. This is completed in combination with costimula-
tory signals typically delivered through theT-cell surface glycopro-
tein, CD28.9 CD28 interactions with B7-1 (CD80) and B7-2
(CD86), costimulatory ligands on antigen-presenting cells, are
essential for initiating antigen-speciﬁc T-cell responses, up-
regulating cytokine expression, and promoting T-cell expansion
and differentiation.9
CTLA4 is a second high-affinity T-cell receptor for both the
B7-1 and B7-2 ligands.9 CTLA4 is a down-regulatory molecule in
T-cell activation, as demonstrated by the lymphoproliferative
phenotype of the CTLA4-deﬁcient mouse strain.10,11 CTLA4-
immunoglobulin (CTLA4-Ig), a soluble fusion protein in which the
extracellular domain of CTLA4 is fused to the heavy chain constant
regions 2 and 3 (CH2-CH3) tail of IgG1, has been shown to be an
effective reagent for blocking CD28-B7 interactions in vivo
because CTLA4-Ig binds to B7-1 and B7-2 ligands and blocks B7
interactions with both CD28 and CTLA4.12 Blockade of the CD28
signaling pathway has been used successfully to prevent T-cell
dependent responses in many animal models of autoimmunity and
transplantation.9,13,14 Very recently, the ﬁrst successful clinical
applications of CTLA4-Ig–mediated blockade of T-cell costimula-
tion have been reported.15,16
We report here evidence that the development of inhibitory
antibodies to factor VIII is T-cell dependent. Moreover, murine
CTLA4-Ig (mCTLA4-Ig) blockade is an effective means of
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suppressing secondary antifactor VIII responses.
Materials and methods
Animals
The characteristics of the E-16 strain of hemophilic mice have been
reported.5,17 Adult male and homozygous E-16 female mice, aged 10-20
weeks, were used for these studies. Blood samples were obtained by orbital
venous plexus bleeding, and the serum was separated by centrifugation at
600g for 3 minutes. The serum samples were stored at 20°C until the
samples were assayed. To avoid severe bleeding and death of animals, ear
tags were not used to identify the mice in some experiments. For this
reason, Figure 1 does not indicate sequential data for individual mice.
Generation of E-16/B7-1 and E-16/B7-2 double knockout mice was
accomplished by cross breeding of E-16 with B7-1 and B7-2 knockout
mice.18 Homozygous E-16/B7-1 and E-16/B7-2 double knockout mice
were identiﬁed by genotype determination.5,18 Reduced factor VIII activity
was veriﬁed using a chromogenic bioassay (Coatest; Chromogenix,
MoIndal, Sweden).17 The factor VIII activity was less then 1% in both
E-16/B7-12/2 and E-16/B7-22/2 mice.
Antigens
Recombinant human factor VIII (Baxter Healthcare, Hyland Division;
Glendale, CA) was used in the study.
Murine CTLA4-Ig
A mCTLA4-Ig complementary DNA (cDNA) expression plasmid was
prepared by ligation of the leader and extracellular domains of mCTLA4 to
the hinge, the CH2 and CH3 domains of IgHg2a that had been mutated to
remove effector functions, as described in Streurer.19 The insert was cloned
into the expression vector pED and stably transfected into Chinese hamster
ovary cells as previously described.20 Concentrated conditioned media was
loaded onto a chromatography column (Protein A Sepharose Fast Flow;
Amersham Pharmacia Biotech, Piscataway, NJ). The column was washed
with phosphate-buffered saline (PBS, pH 7.1), and the mCTLA4-Ig was
eluted with 20 mmol/Lcitrate (pH 3.0). The peak pool was neutralized with
1 mol/L tris(hydroxymethyl) aminomethane (Tris, pH 8.0) to a ﬁnal pH of
7.5 and formulated into PBS (pH 7.1) using an Amicon-stirred cell with a
YM30 membrane (Millipore Corp, Bedford, MA). The mCTLA4-Ig was
depyrogenated using a chromatography column (Poros PI; Perceptive
Biosystems, Framingham, MA), and the product was eluted from the
column in a linear sodium chloride (NaCl) gradient from 0 to 1 mol/LNaCl
in 25 mmol/LTris (pH 7.5).The mCTLA4-Ig was then formulated into PBS
(pH 7.1) using anAmicon-stirred cell with a YM30 membrane.
Antibody measurements
The antifactor VIII titer was determined by enzyme-linked immunosorbent
assay (ELISA).6 The ELISA tests were carried out using microtiter wells
coated with 0.8 µg/mL recombinant human factor VIII in 0.05 mol/L
carbonate-bicarbonate (pH 9).After mouse plasma samples were incubated
in the wells at 4°C overnight and then washed, alkaline-phosphatase–
conjugated goat antimouse IgG (Southern Biotechnology Associates,
Birmingham, AL) was added for 2 hours at room temperature. After
washing, we added 2 mg/mL P-nitrophenyl phosphate (Sigma, St. Louis,
MO) in 100 mmol/L glycine, 1 mmol/L magnesium dichloride (MgCl2),
and 2 mmol/L zinc dichloride (ZnCl2) (pH 10.4). The absorbance was read
at 410 nm using an automated micro titer plate ELISA reader. The
concentration of antifactor VIII antibody was estimated from a standard
curve obtained using a factorVIII monoclonal antibody (mAb) that binds to
theA2 domain, mAb 413.21 The titer was calculated from points that fell on
the linear portion of the assay standard curve.AntifactorVIII inhibitor titers
in Bethesda units (BU) were measured by the Bethesda assay.22
T-cell proliferation assays
The spleen was used as the source of T cells for proliferation assays. Spleen
cells were then cultured (5 3 105 cells/well) in 96-well ﬂat-bottom plates.
Varying amounts of recombinant factor VIII were added to the culture
medium consisting of complete RPMI 1640 (Gibco BRL, Rockville, MD)
containing 0.5% hemophilic mouse serum. After 72 hours of culture at
37°C, we added 0.074 MBq (2 µCi) 3H-thymidine/well (ICN Pharmaceuti-
cals, Irvine, CA). The cultures were harvested 16 hours later (Matrix 9600;
Packard, Meriden, CT). Data are expressed as the mean for triplicate wells
of the cpm incorporated into insoluble DNA.
Results
Primary immune response to factor VIII
The roles of B7-1 and B7-2 costimulatory ligands present on
antigen-presenting cells were evaluated to determine if the T-cell
CD28 signaling pathway is essential for the development of
inhibitory antibodies to factor VIII. To do this we crossed
hemophilia A mice with B7-12/2 and B7-22/2knockout mice.18,23
Mice deﬁcient in both factor VIII and either B7-1 or B7-2 ligands
were selected by genotype analysis.The hemophiliaA/B7-12/2 and
hemophilia A/B7-22/2mice were then injected intravenously with
0.2 µg human factor VIII at 2-week intervals.After 4 injections, all
9 hemophilia A/B7-12/2mice had developed antifactor VIII, with
ELISAantibody titers greater than 350 µg/mLand a mean inhibitor
level of 712 BU (Figure 1). These are values similar to those for
otherwise normal hemophilia A mice injected with factor VIII.6 In
contrast, none of the 8 hemophilia A/B7-22/2mice had detectable
antifactor VIII.
To evaluate the T-cell response of these B7-1– and B7-2–
deﬁcient hemophilia A mice, spleen cells were obtained 3 days
after a ﬁfth intravenous injection of factor VIII. The T-cell
proliferative activity determined by 3H-thymidine incorporation
showed a factor VIII dose-dependent response for cells from the
hemophilia A/B7-12/2mice (Figure 2). In contrast, T-cell response
was not detected at any factor VIII level for spleen cells from
hemophilia A/B7-22/2mice. Thus, the B7-2 ligand is essential for
the development of an immune response to factor VIII injected
Figure 1. The role of B7-1 and B7-2 antigens in the antifactor VIII antibody
response. Hemophilia A/B7-12/2 (s) and hemophilia A/B7-22/2 (d) mice were
injected intravenously with 0.2 µg factor VIII at 2-week intervals. Serum samples for
antifactor VIII assay were obtained 12 days after the second and sixth factor VIII
injections.
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is missing.
Blocked induction of an antifactor VIII response by mCTLA4-Ig
As mCTLA4-Ig has been shown to be an effective reagent for
blocking CD28-B7-2 interactions in vivo,12 we tested the effective-
ness of this blockade of the CD28 signaling pathway in preventing
antifactor VIII inhibitor antibody formation.Antifactor VIII inhibi-
tory antibodies were induced in control hemophilia A mice by
repeated intravenous injections of 1 µg recombinant human factor
VIII at 3-week intervals (group G-1, Figure 3).Antifactor VIII was
detected in 4 of the 5 mice 20 days after the ﬁrst injection, and all
control mice developed high-titer antifactor VIII after receiving 2
to 4 injections.The mean inhibitor level after 4 injections was 1860
BU. Antifactor VIII antibody formation was markedly suppressed
in mice injected intraperitoneally with 250 µg of murine CTLA4-Ig
on the day before and the day after the ﬁrst factor VIII injection
(groupG-2,Figure3),eventhoughtherewasnofurthermCTLA4-Ig
given with 3 subsequent factor VIII injections on days 23, 44, and
66. Antifactor VIII was not detectable in any group G-2 mice after
the ﬁrst or second factor VIII injection. Three weeks after the third
injection of factor VIII, a weak immune response was detected in 2
of the 6 mice in group G-2.
To investigate if the limited duration of unresponsiveness is a
result of the short half-life of human factor VIII in these mice (4-5
hours in murine hemophilia A8), control and mCTLA4-Ig–treated
mice (groups G-3 and G-4, Figure 3) were injected with 1 µg factor
VIII intravenously on day 0. This was followed by daily intraperi-
toneal injections of 1 µg factor VIII on days 2-12. On day 20,
high-titer antifactor VIII was present in the control mice (group
G-3), as determined by ELISA, and the mean inhibitor titer was
694 BU. In contrast, the group G-4 mice that were injected with
mCTLA4-Ig on the day before and the day after the ﬁrst exposure
to factor VIII had no detectable antifactor VIII on day 20. The
delayed antifactor VIII antibody response after 3 additional factor
VIII injections was the same in these mice as that in the group G-2
animals. Thus, the limited persistence of factor VIII in the plasma
after CTLA4-Ig injection was not the reason for a limited duration
of unresponsiveness in CTLA4-Ig– treated mice.
Because a delayed antifactor VIII response was detected after
repeated factor VIII infusions when mCTLA4-Ig was given only at
the time of the ﬁrst factor VIII exposure, we determined if
mCTLA4-Ig might prevent antifactor VIII development if given
with each factor VIII infusion. In that experiment (Figure 4),
hemophilia A mice were simultaneously infused 6 times at 3-week
intervals with both factor VIII and mCTLA4-Ig. There was no
detectable antifactor VIII in any of 10 mice treated in this manner
when they were tested 4 weeks after the sixth factor VIII injection.
In contrast, high-titer antifactor VIII was present in serum from
mice that had received only 1 mCTLA4-Ig injection (at the time of
the ﬁrst exposure to factor VIII) followed by 5 injections of factor
VIII alone.
These mCTLA4-Ig–treated mice were then tested to determine
if they would have an immune response after additional factor VIII
injections in the absence of mCTLA4-Ig. After 2 intravenous
injections at 3-week intervals, none of the 5 mice developed
antifactor VIII, while low-level antifactor VIII was detected in 2 of
4 control mice not previously exposed to either factor VIII or
Figure 2. T-cell response to factor VIII for hemophilia A/B7-12/2 and hemophilia
A/B7-22/2 mice. Spleen cells were obtained 3 days after the ﬁfth intravenous
injection of human factor VIII. Pooled spleen cells from 3 mice were used to establish
the proliferation data. The open and closed squares are for cells from untreated
hemophiliaA/B7-12/2 and B7-22/2mice. Five intravenous injections of factor VIII were
given to hemophilia A/B7-12/2mice (s) and hemophilia A/B7-22/2mice (d). The
concentration of factor VIII in the cultures is indicated on the horizontal axis.
Figure 3. The effect of mCTLA4-Ig on antifactor VIII antibody formation. Four
groups of hemophilia A mice were injected with recombinant human factor VIII on
days 0, 23, 44, and 66 (initially 1 µg intravenously and then 0.2 µg for the second,
third, and fourth injections). Mice in groups G-3 and G-4 were also injected
intraperitoneally with 0.2 µg factor VIII on days 2-12. Blood samples for the antifactor
VIII assay were obtained on days 20, 37, 58, and 82. Control groups G-1 and G-3 (s)
were injected with only factor VIII. Groups G-2 and G-4 (d) were also injected
intraperitoneally with 250 µg mCTLA4-Ig on the day before and the day after the ﬁrst
factor VIII injection. The antifactor VIII antibody concentration was determined by
ELISA. Antifactor VIII assay data points indicated as less than 0.16 µg/mL were
similar to those for plasma samples obtained from unimmunized hemophiliaAmice.
Figure 4. The effect of repeated administration of mCTLA4-Ig on antifactor VIII
antibody formation. After the ﬁrst injection, which contained both factor VIII and
mCTLA4-Ig, hemophiliaAmice were injected intravenously, at 3-week intervals, with
both 1 µg factor VIII and 250 µg mCTLA4-Ig (d) or with factor VIII alone (s). Serum
samples for the antifactor VIII assay were obtained 4 weeks after the sixth factor VIII
injection.
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mean factor VIII titer was 93 µg/mL for mice that had previously
received both factor VIII and mCTLA4-Ig, while the mean titer
was 155 µg/mL for the control mice. These data document the
limits of antigen-speciﬁc immune suppression that followed from
repeated coadministration of mCTLA4-Ig with factor VIII.
Secondary immune response to factor VIII suppressed
by mCTLA4-Ig
To determine if mCTLA4-Ig modiﬁes a secondary immune re-
sponse to factorVIII, we injected mCTLA4-Ig at the same time that
factor VIII was given to hemophilia A mice that had already
developed antifactor VIII. Initially, all the hemophilia A mice had
been injected 3 times with 0.2 µg factor VIII, and the level of
antifactor VIII was determined by ELISA. The control mice then
received 3 additional injections of factor VIII, while the remaining
mice were given mCTLA4-Ig at the same time as they received the
ﬁrst of 3 additional factor VIII injections. While many mice died of
bleeding complications during this experiment because of the
repeated injections and blood sample collections, the results were
clearly different for the 2 groups.An increase in the antifactor VIII
titer was noted after the fourth injection of factor VIII for the
control mice, with the mean titer ranging from 16 to 230 µg/mL
(Figure 6A). After the ﬁfth factor VIII injection, all antifactor VIII
titers were greater than 350 µg/mLin the 4 remaining control mice.
In contrast, mice treated with mCTLA4-Ig at the fourth factor VIII
injection had minimal or no increases in antifactor VIII (Figure 6B
and C). The administration of mCTLA4-Ig (Figure 6C) inhibited
this secondary immune response to factor VIII in mice that had
already developed relatively high antifactor VIII levels (5-90 BU).
This also occurred in mice with minimal antifactor VIII after the 3
initial injections (less than 5 BU; Figure 6B).
Discussion
We used a mouse model of hemophilia A to establish the T-cell
dependence of inhibitory antibody formation to factor VIII and to
evaluate the potential use of a reagent that blocks the B7/CD28/
CTLA4 costimulation pathway. The murine fusion protein,
mCTLA4-Ig, blocks this pathway, and it prevented the initiation
of the antibody response and suppressed the development of a secondary antibody response to factor VIII. These data gave
direct evidence, for the ﬁrst time, that the antibody response to
factor VIII is T-cell dependent and can be modulated by costimula-
tory blockade.
While these studies in mice were done with recombinant human
factor VIII, we believe that they are relevant for our efforts to
prevent and treat factor VIII inhibitor antibodies in patients with
hemophilia A. As a practical matter, mouse factor VIII is not
available in the quantity and purity needed to carry out these
experiments. While the gene has been cloned, the protein has not
been produced in quantity by recombinant technology. Moreover,
as the hemophilic mice lack mouse factor VIII, having no
detectable factor VIII activity in their plasma and no detectable
factor VIII light chain protein by immunoassay,17 they would be
expected to respond to both human and mouse factor VIII as
completely foreign proteins.While it is possible that there are some
‘‘mouse-speciﬁc’’ determinants on murine factor VIII that are
shared with other mouse proteins, this would only make the
response to human factor VIII somewhat greater than that to mouse
factor VIII. However, since we have demonstrated that the
Figure 5. The effect of simultaneous administration of mCTLA4-Ig and factor
VIII. Hemophilia A mice treated as described for Figure 4, with 6 injections of both
factor VIII and mCTLA4-Ig, were subsequently given 6 intravenous injections of 0.2
µg of factor VIII at 3-week intervals without additional mCTLA4-Ig (d). Control mice
with no prior factor VIII exposure were immunized in parallel (s). Serum samples for
the antifactor VIII assay were obtained 3 weeks after the second and sixth injections.
Figure 6. The effect of mCTLA4-Ig on the secondary immune response to factor
VIII. All mice initially received 3 intravenous injections of 0.2 µg factor VIII at 2-week
intervals. (A) Control mice (s) were then injected with factor VIII an additional 3 times,
and blood samples were obtained for assay. (B, C) The other mice (d) were injected
intraperitoneally with 250 µg mCTLA4-Ig the day before and the day after the fourth
factor VIII injection (as indicated by the arrow).This was followed by 2 more injections
of only factor VIII at 3-week intervals. The number of factor VIII injections prior to the
blood sample tested for antifactor VIII is indicated on the horizontal axis.
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the response to human factor VIII would be, if anything, more
difficult to prevent.
To the extent possible, the experimental design incorporated all
concerns that may be important in the application of costimulatory
blockade in patients. For this reason, the dose chosen for most
studies, 0.2 µg factor VIII per intravenous injection, was compa-
rable to that of a single therapeutic dose given to a patient with
severe hemophiliaA(with the goal of raising the plasma factorVIII
level to 100%). For the initial experiments, the blockade was
limited to a single pair of injections of mCTLA4-Ig at the time of
the ﬁrst factor VIII exposure, an approach that would be expected
to have less effect on the patient’s overall immunologic status than
repeated CTLA4-Ig administration at each factor VIII injection.
However, our experiments showed that an immune response to
factor VIII returned 6-9 weeks after a single pair of CTLA4-Ig
injections (Figure 1) or even after a series of 6 paired injections of
factor VIII and CTLA4-Ig at 3-week intervals (Figure 3). The latter
experiment did demonstrate, however, that blockade of antifactor
VIII antibody was maintained while CTLA4-Ig was given at
3-week intervals over a 5- month period (Figure 2).
It is not certain why the hemophilic mice formed antifactor VIII
after they were given additional factor VIII injections in the
absence of mCTLA4-Ig. However, similar reversal of speciﬁc
unresponsiveness to a T-dependent antigen (sheep red blood cells
[SRBC]) has been described by Wallace and colleagues.24 In those
studies, a single dose of murine CTLA4-Ig prevented antibody
formation immediately after the ﬁrst and second SRBC injections,
but a high-titer response followed the third SRBC injection. Their
experiments also showed that unresponsiveness to SRBC persisted
while mice were successfully immunized with a different T-
dependent antigen. Finally, T and B cells from unresponsive mice
were shown to be functional when transferred to irradiated mice
subsequently immunized with SRBC. Thus, they had been neither
depleted of responsive cells nor rendered permanently ‘‘tolerant’’
by CTLA4-Ig.24
In our studies, the development of antifactor VIII after repeated
antigen exposure is likely to be due to the combination of
mCTLA4-Ig clearance over time (its serum half-life b-phase being
6 days24) and emigration from the thymus of naive T cells that are
capable of an antifactor VIII response.25 However, Wallace et al24
found that mice thymectomized before the initial exposure to
SRBC and CTLA4-Ig also develop anti-SRBC after the third
injection. The down-regulatory role of B7-CTLA4 interactions is
also important in the induction and maintenance of T-cell anergy.14
Thus, CTLA4-Ig blockade of the B7-CTLA4 interaction could also
prevent maintenance of anergy in hemophiliaAmice.
Blockade of CD28/B7 interactions using either CTLA4-Ig or
anti-B7 antibodies has previously been shown to be an effective
method for blocking T-cell responses in several in vivo animal
models of transplantation and autoimmunity9 and in recent clinical
studies.15,16,26,27 CD28 is expressed constitutively on T cells, and
the ligands for CD28, B7-1 and B7-2, are expressed on B cells as
well as other antigen-presenting cells such as dendritic cells and
monocytes. Blockade of CD28 signaling in T cells results in a
failure in the activation of the antigen-speciﬁc T-cell subset.
In the absence of CD28 costimulation and IL-2 production,
T-cell activation does not occur efficiently. In vitro, exposure of T
cells to antigens in the absence of costimulation can render a T cell
unresponsive to reactivation, a condition termed anergy.28 Whether
this mechanism is effective in vivo is unknown. Additional effects
of costimulation blockade on the T-cell–B-cell interactions in the
germinal centers may be critical in preventing antibody formation.
Because the blockade of the B7-1 and B7-2 ligands individually
can lead to distinct effects in models of autoimmune disease, it has
been suggested that B7-1 and B7-2 may have unique biological
roles.29,30 Alternatively, the earlier expression of B7-2 has sug-
gested a greater role for B7-2 in initiating a T-cell response and a
role for B7-1 in amplifying or regulating aT-cell response.We have
examined the roles of B7-1 and B7-2 in the initiation of the
antifactor VIII antibody response using hemophilia A mice deﬁ-
cient for the expression of either B7-1 or B7-2. Although the
antibody response was not signiﬁcantly altered in the B7-1
deﬁcient mice, the B7-2 deﬁcient mice formed no detectable
antifactor VIII antibodies (Figure 1). In addition, the T-cell
proliferative response to factor VIII was greatly suppressed in the
B7-2 deﬁcient mice, although it was normal in B7-1 deﬁcient mice
(Figure 2). This indicates that the B7-2 ligand is critical for T-cell
priming in hemophiliaAmice given factor VIII intravenously.
B7-2 is expressed in lymph node germinal centers of both
humans and mice,31,32 and the blockade of B7-2 in mice has been
shown to block antibody affinity maturation in germinal centers
and to impair the development of B-cell memory.32 Moreover,
studiesoftheT-cell–dependentantibodyresponsetothetrinitrophe-
nol (TNP) hapten in B7-1– and B7-2–deﬁcient mice indicated that
B7-2 is essential for isotype switching and for the formation of
germinal centers when antigen is given intravenously and in the
absence of an adjuvant.18 Under those conditions of antigen
administration, B7-1 did not compensate for the absence of B7-2,
while B7-1–deﬁcient mice generated an antibody response compa-
rable to wild type mice.14,18 However, mice lacking either B7-1 or
B7-2 antigens had high-titer TNP-speciﬁc IgG responses when
immunized subcutaneously with TNP in complete Freund’s adju-
vant. Mice lacking both B7-1 and B7-2 antigens, however, failed to
class switch or form germinal centers when immunized using these
conditions. Thus, B7-1 and B7-2 antigens can have compensating,
overlapping roles for isotype switching and germinal center
formation when inﬂammation leads to up-regulation of B7-1 and
B7-2 expression.14,18
The formation of inhibitory antibodies to factor VIII is a critical
problem for hemophiliaApatients treated with protein replacement
therapy and may be a major problem for gene therapy in
hemophilic patients. The results of our studies with the hemophilia
Amouse suggest that a costimulation blockade may be an effective
therapy for the prevention of antifactor VIII antibodies in these
patients. Data from the B7-2–deﬁcient mice suggest that the
blockade of the CD28–B7-2 interaction is more important in the
prevention of an antibody response to factor VIII injected intrave-
nously and that anti–B7-2 may be as effective as CTLA4-Ig in
blocking the initiation of an antifactor VIII response. If this is the
case, B7-1 function would remain intact, and the treatment could be
less generally immunosuppressive than would be the case if
CTAL4-Ig were used.
Although we have not veriﬁed that the antibody-free hemo-
philia A mice treated with CTLA4-Ig have normal factor VIII
recovery after an infusion of factor VIII, published studies have
addressed this question.33 Using immunologic and coagulation-
based assays, gene therapy experiments with this mouse model of
hemophilia A have documented normal factor VIII recovery and
clearance in mice treated with a human factor VIII–encoding
adenoviral vector when their plasma was free of antifactor VIII.33
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hemophilia A patients will develop inhibitory antibodies after
factor VIII treatment.1,2 For this reason, the clinical application of
our studies would be primarily for patients who have already
developed detectable antifactor VIII. In evaluating this possibility,
the ability of anti–B7-2 to block antibody-affinity maturation32
suggests that blockade of the B7/CD28 pathway might be effective
in suppressing a secondary antifactor VIII antibody response, at
least in part, by preventing maturation of the B-cell response. In the
single experiment reported here (Figure 6), combined treatment of
hemophilia A mice with CTLA4-Ig and factor VIII after detection
of antifactor VIII antibody prevented a further increase in antibody
titer in most mice and a fall in titer in some. If the pattern is similar
in patients, B7-2 costimulation blockade at the time of factor VIII
treatment may stabilize the inhibitor level for patients treated early
after detection of antifactor VIII. For low-titer factor VIII inhibitor
patients, this costimulation blockade might then permit an escala-
tion of factor VIII doses to therapeutically effective levels without
further boosting the inhibitor titer. As antibody suppression by
costimulation blockade appears to last several weeks, intermittent
dosing may then be sufficient to prevent or modulate inhibitor
formation. In this way, therapeutic costimulation blockade would
reduce antifactor VIII while leaving the immune responses to other
antigens intact.
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